Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pyrilamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.97 |
| ▸ | LMNA | P02545 | 4/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.97 |
| ▸ | DRD1 | P21728 | 4/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.97 |
| ▸ | HTR2A | P28223 | 3/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 2/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 2/20 | 0.97 |
| ▸ | HTR2B | P41595 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrilamine SCHEMBL19114 | 0.99 | LMNA (1.00) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL29444024 | 0.99 | LMNA (1.00) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28823277 | 0.97 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL22118219 | 0.97 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28350675 | 0.97 | LMNA (0.97) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28086659 | 0.96 | LMNA (0.95) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL622845 | 0.96 | LMNA (0.95) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL4075657 | 0.94 | LMNA (0.90) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL4450392 | 0.92 | CHRM2 (0.86) | LMNACHRM2ADRA2ADRD1SLC6A4 | |
| Pyrilamine SCHEMBL28032666 | 0.92 | LMNA (0.86) | LMNACHRM2ADRA2ADRD1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118021984-A | Compound external preparation, preparation method and application thereof | 南方医科大学 | 2024-05-14 | — | — | CN | claimed |
| EP-0608322-B1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON VICKS INC (US) | 1998-07-22 | — | — | EP | claimed |
| US-5756118-A | CONSISTS OF AQUEOUS CARRIER, AN ANTIHISTAMINE DRUG AND NONIONIC POLYACRYLAMIDE BEING PREDISPERSED IN WATER-IMMISCIBLE OIL CONTAINING SURFACTANT HAVING HYDROPHILIC-LIPOPHILIC BALANCE ABOUT 7 TO 10 | RICHARDSON-VICKS INC. (US) | 1998-05-26 | — | — | US | claimed |
| EP-0608320-B1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON VICKS INC (US) | 1998-01-28 | — | — | EP | claimed |
| EP-0652774-B1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | PROCTER & GAMBLE (US) | 1997-05-07 | — | — | EP | claimed |
| US-5614178-A | TRANSDERMAL | THE PROCTER & GAMBLE COMPANY (US) | 1997-03-25 | — | — | US | claimed |
| EP-0652774-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER. | PROCTER & GAMBLE (US) | 1995-05-17 | — | — | EP | claimed |
| EP-0608320-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| EP-0608322-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1994-08-03 | — | — | EP | claimed |
| WO-1994002176-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL USE CONTAINING A CROSSLINKED CATIONIC POLYMER AND AN ALKOXYLATED ETHER | THE PROCTER & GAMBLE COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| WO-1993007902-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| WO-1993007903-A1 | ENHANCED SKIN PENETRATION SYSTEM FOR IMPROVED TOPICAL DELIVERY OF DRUGS | RICHARDSON-VICKS, INC. (US) | 1993-04-29 | — | — | WO | claimed |
| CN-118021984-A | Compound external preparation, preparation method and application thereof | 南方医科大学 | 2024-05-14 | — | — | CN | disclosed |
| CN-117224418-B | Anti-aging composition and product application thereof | 杭州湃肽生化科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-117255696-A | Chewable formulation | 葛兰素史克消费保健（美国）控股有限责任公司 | 2023-12-19 | — | — | CN | disclosed |
| CN-117224418-A | Anti-aging composition and product application thereof | 杭州湃肽生化科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-1993018764-A2 | VERAPAMIL HCl FORMULATION AND OTHER OPHTHALMIC SOLUTIONS WITH BUFFER SYSTEM FOR OCULAR ADMINISTRATION | COOPERVISION PHARMACEUTICALS, INC. (US) | 1993-09-30 | — | — | WO | disclosed |
| WO-1993003723-A1 | LEUKOTRIENE RECEPTOR ANTAGONIST-ANTIHISTAMINE COMPLEX | ALLERGAN, INC. (US) | 1993-03-04 | — | — | WO | disclosed |
| EP-0397044-A2 | Arylsulfonamides, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-11-14 | — | — | EP | disclosed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | disclosed |